Document is current
Any future updates will be listed below
-
Authors
Pareja, Fresia https://orcid.org/0000-0003-3748-8049
Bhargava, Rohit https://orcid.org/0000-0002-1225-8418
Borges, Virginia F. https://orcid.org/0000-0003-1158-7524
Brogi, Edi https://orcid.org/0000-0003-4737-8468
Canas Marques, Rita
Cardoso, Fatima https://orcid.org/0000-0002-6692-2249
Desmedt, Christine https://orcid.org/0000-0002-5223-5579
Harigopal, Malini
Lakhani, Sunil R. https://orcid.org/0000-0003-1879-2555
Lee, Adrian https://orcid.org/0000-0001-9917-514X
Leone, Jose Pablo https://orcid.org/0000-0002-8537-652X
Linden, Hannah
Lord, Christopher J. https://orcid.org/0000-0002-3226-0515
Marchio, Caterina https://orcid.org/0000-0003-2024-6131
Merajver, Sofia D. https://orcid.org/0000-0002-6823-7130
Rakha, Emad https://orcid.org/0000-0002-5009-5525
Reis-Filho, Jorge S. https://orcid.org/0000-0003-2969-3173
Richardson, Andrea https://orcid.org/0000-0001-5221-1094
Sawyer, Elinor https://orcid.org/0000-0001-8285-4111
Schedin, Pepper https://orcid.org/0000-0003-4244-987X
Schwartz, Christopher J. https://orcid.org/0000-0002-8086-8429
Tutt, Andrew https://orcid.org/0000-0001-8715-2901
Ueno, Naoto T.
Vincent-Salomon, Anne https://orcid.org/0000-0001-5754-5771
Weigelt, Britta https://orcid.org/0000-0001-9927-1270
Wen, Y. Hannah
Schnitt, Stuart J. https://orcid.org/0000-0002-3608-7828
Oesterreich, Steffi https://orcid.org/0000-0002-2537-6923
-
Funding
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Cancer Institute (P50 CA24779 01, P30CA008748)
Starr Foundation
Breast Cancer Research Foundation (AACR-BRCF 09-06-26BORG)
Robert F. and Patricia-Young Endowed Chair in Young Women’s Breast Cancer
Cancer Research UK
Breast Cancer Now
JSRF was funded by the Breast Cancer Research Foundation when this review was conceived.
P.S. is the Leonard Schnitzer Endowed Chair in Breast Oncology
B.W. is supported in part by a Cycle for Survival grant.
- License Information
-
More Information
Article History
Received: 30 May 2024
Accepted: 9 January 2025
First Online: 24 January 2025
Competing interests
: The Authors declare no Competing Non-Financial interests but the following Competing Financial Interests. F.P. is a member of the scientific advisory board of MultiplexDx. In addition, F.P. serves on the diagnostic advisory board and reports receiving consultancy fees from AstraZeneca. R.B. reports receiving consulting fees from GE Health Care and is on the speaker’s bureau for AstraZeneca. V.F.B. reports consulting fees from Gilead, AstraZeneca and Seagen (now Pfizer), as well as Research funds to her institution from Gilead, AstraZeneca, Seagen/Pfizer and Olema. S.L. has received honoraria to his University from AstraZeneca and Roche. J.P.L. receives research funding from Kazia Therapeutics and Lilly, and consultancy fees from Minerva Biotechnologies. C.J.L. received and/or has received research funding from AstraZeneca, Merck KGaA, Artios, Neophore, has received consultancy, scientific advisory board membership or honoraria payments from FoRx, Syncona, Sun Pharma, Gerson Lehrman Group, Merck KGaA, Vertex, AstraZeneca, Tango Therapeutics, 3rd Rock, Ono Pharma, Artios, Abingworth, Tesselate, Dark Blue Therapeutics, Pontifax, Astex, Neophore, Glaxo Smith Kline, Dawn Bioventures, Blacksmith Medicines, ForEx, has stock in Tango, Ovibio, Hysplex, Tesselate. C.J.L. is also a named inventor on patents describing the use of DNA repair inhibitors and stands to gain from their development and use as part of the ICR “Rewards to Inventors” scheme and also reports benefits from this scheme associated with patents for PARP inhibitors paid into C.J.L.’s personal account and research accounts at the Institute of Cancer Research. C.M. has received personal consultancy fees from Bayer, AstraZeneca, Menarini, Roche and speaker fees from Veracyte, Illumina, Daiichi Sankyo. S.J.S. is on the scientific advisory boards of Ibex Medical Analytics and PreciseDx. B.W. reports research funding from Repare Therapeutics paid to the institution, and employment of an immediate family member at AstraZeneca.
